ImmunityBio (NASDAQ:IBRX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $24.00 target price on the stock.

Several other research analysts have also recently weighed in on the company. Piper Sandler boosted their price target on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday. Jefferies Financial Group lifted their price objective on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

ImmunityBio Stock Up 17.4%

Shares of NASDAQ:IBRX opened at $6.48 on Tuesday. The firm has a market capitalization of $6.38 billion, a PE ratio of -15.80 and a beta of 0.03. The company has a 50-day moving average price of $2.44 and a two-hundred day moving average price of $2.49. ImmunityBio has a twelve month low of $1.83 and a twelve month high of $7.98.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.06 million for the quarter, compared to analysts’ expectations of $31.88 million. Analysts anticipate that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of ImmunityBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its holdings in ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock valued at $134,000 after buying an additional 29,297 shares during the period. Rhumbline Advisers increased its position in ImmunityBio by 5.6% during the first quarter. Rhumbline Advisers now owns 219,360 shares of the company’s stock valued at $660,000 after acquiring an additional 11,573 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of ImmunityBio in the second quarter valued at $43,000. Wealth Effects LLC lifted its holdings in shares of ImmunityBio by 23.9% in the 2nd quarter. Wealth Effects LLC now owns 122,000 shares of the company’s stock worth $322,000 after acquiring an additional 23,500 shares during the last quarter. Finally, Plancorp LLC purchased a new position in shares of ImmunityBio during the 2nd quarter worth about $717,000. Institutional investors own 8.58% of the company’s stock.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA end-of-phase meeting: ImmunityBio said it held a Type B meeting with the FDA and plans to submit additional information within 30 days as part of a potential resubmission path for the ANKTIVA sBLA in papillary non‑muscle invasive bladder cancer — a clearer regulatory route is viewed as materially positive for the drug’s label expansion and commercial prospects. ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® …
• Positive Sentiment: Market coverage reports and investor reaction: Multiple outlets highlight the FDA discussion as the proximate cause of the rally, emphasizing that the agency outlined next steps for resubmission and label expansion — this narrative has driven heavy buying interest. Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA …
• Positive Sentiment: Clinical data momentum: Updated study results for the company’s off‑the‑shelf CAR‑NK / CD19 t‑haNK programs reported durable complete responses in Waldenström lymphoma without chemo or lymphodepletion — positive clinical data can boost longer‑term valuation upside. ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results
• Positive Sentiment: Analyst support: D. Boral Capital reaffirmed a buy rating and published a $24 price target, signaling bullish institutional sentiment that may encourage additional inflows. Benzinga
• Neutral Sentiment: Press and news flow: Multiple outlets (Investing.com, The Pharma Letter, Benzinga, Blockonomi, MSN) are amplifying the FDA and clinical stories — broader coverage increases visibility but doesn’t change fundamentals by itself. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: High volatility and fundamentals remain mixed: despite the rally, the company is forecast to report negative EPS for the year and the stock has proven highly volatile — some commentators include IBRX on watchlists of speculative or high‑risk healthcare names. That risk could prompt quick profit‑taking if regulatory or data follow‑ups disappoint. Top 3 Health Care Stocks You May Want To Dump In January

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.